文献速递肝病消化道肿瘤与早癌

美国全国性队列:慢性乙型肝炎常规实践中的初始评估、长期监测与肝癌监测

Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

该研究基于美国Truven MarketScan数据库(2007-2014)纳入55,317例慢性乙型肝炎患者,评估初始评估与长期监测的指南依从性。结果显示初始评估中59%同时检测ALT和HBV DNA,仅33%检测ALT、HBV DNA和HBeAg;长期监测中仅25%每年同时检测ALT和HBV DNA;高危人群肝癌监测率不足40%。专科就诊是依从性的预测因素。

要点

  • 慢性乙型肝炎初始评估中仅33%完成ALT、HBV DNA和HBeAg三项检测。
  • 长期监测中仅25%患者每年同时检测ALT和HBV DNA。
  • 肝癌高危人群 annual surveillance 率不足40%,25%从未监测。

核心结论

  • 在大型全国性慢性乙型肝炎队列中,初始评估和长期监测的指南依从性较差,专科就诊是依从性的预测因素。

研究设计与样本

  • 基于Truven MarketScan数据库(2007-2014)的商业保险及Medicare补充保险人群的回顾性队列研究,共纳入55,317例慢性乙型肝炎成人患者。

主要发现

  • 平均年龄46±12岁,58%为男性,14.8%有肝硬化,平均随访3.2±2.3年,55.8%有专科就诊。
  • 初始评估中59%同时检测ALT和HBV DNA,33%检测ALT、HBV DNA和HBeAg。
  • 长期监测中仅25%每年同时检测ALT和HBV DNA。
  • 肝癌高危患者中不足40%接受年度肝癌监测,25%研究期间从未监测。
  • 代偿性肝硬化与专科就诊是初始评估和长期监测达标的预测因素(OR分别为1.60和1.47;1.86和1.31,均P<0.001)。

关键数值与推荐

  • 初始评估达标定义为检测ALT和HBV DNA,或检测ALT、HBV DNA和HBeAg。
  • 长期监测达标定义为每年同时检测ALT和HBV DNA。
  • 肝癌高危人群定义为肝硬化患者、无肝硬化男性>40岁、无肝硬化女性>50岁。

临床怎么用

  • 应加强慢性乙型肝炎患者的初始评估和长期监测,尤其关注非专科就诊患者。
  • 对肝癌高危患者应提高年度肝癌监测的覆盖率。
  • 促进专科就诊可能改善指南依从性。

局限性

  • 研究基于保险理赔数据库,可能存在编码不准确和未记录检测的情况。
  • 仅纳入有商业保险或Medicare补充保险的患者,结果外推需谨慎。
  • 回顾性设计无法确定因果关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Previous studies, mostly small and single center, have shown gaps in the evaluation and monitoring of patients with chronic hepatitis B (CHB) virus infection. We aimed to examine the rates and predictors of adherence to guidelines for CHB care in a large nationwide cohort. METHODS: We identified adult patients with CHB infection from the Truven MarketScan databases of commercially insured and Medicare patients with private insurance supplement (2007-2014) using International Classification of Diseases, Ninth Revision, Clinical Modification codes. The initial evaluation cohort had at least 6 months follow-up, whereas at least 12 months was required for the long-term monitoring cohort. RESULTS: We analyzed 55,317 eligible patients with CHB infection: mean age 46 ± 12 years, 58% men, and 14.8% with cirrhosis. Over a mean follow-up of 3.2 ± 2.3 years, 55.8% had specialist (gastroenterology or infectious diseases) visits. For initial evaluation, 59% of patients received both alanine aminotransferase (ALT) and hepatitis B virus (HBV) DNA tests, whereas only 33% had ALT, HBV DNA, and hepatitis B e antigen tests, with higher frequencies among patients with specialist visits. For long-term monitoring, only 25% had both ALT and HBV DNA tests performed annually. Among patients at higher risk of developing hepatocellular carcinoma (patients with cirrhosis, male patients without cirrhosis older than 40 years, and female patients without cirrhosis older than 50), less than 40% underwent annual hepatocellular carcinoma surveillance, with 25% never receiving surveillance during the study period. Predictors of optimal initial evaluation and long-term monitoring were compensated cirrhosis (odds ratio: 1.60 and 1.47, respectively) and specialist visits (odds ratio: 1.86 and 1.31, respectively) (both P < 0.001). DISCUSSION: In this large cohort of patients with CHB infection with private insurance or Medicare with private insurance supplement, we observed poor adherence to the recommended initial evaluation and long-term monitoring. Among the predictors of adherence were specialist visits. Further efforts are needed to identify barriers and improve access to care.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Tran S, Jeong D, Henry L, et al. Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. Am J Gastroenterol. 2021. PMID: 33927125. doi:10.14309/ajg.0000000000001271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。